Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Curr Opin Oncol. 2014 Mar;26(2):184-95. doi: 10.1097/CCO.0000000000000058.
The Hedgehog pathway has been identified as a key element in the development of many forms of cancer. Smoothened (Smo) inhibitors are known to beneficially interfere with the Hedgehog pathway and are currently under investigation as anticancer drugs for many tumor entities. Reviewed here are the most recent developments in clinical research on Smo inhibitors for the treatment of advanced basal cell carcinoma (BCC).
When reviewing the literature of the past 12 months, it is striking to see the rapid evolution of the field. Compounds that have been presented as powerful new drug candidates 12 months ago have now been discontinued, whereas new ones have emerged. Reports on 13 drug candidates have been identified: one marketed, vismodegib, eight currently under development (phase I-II) and four for which clinical investigation for BCC is currently not being pursued.
Smo inhibitors are a promising drug class for the treatment of BCC. To date, most candidates are in early stage development and are expected to enter the market in approximately 5-8 years, if successful.
Hedgehog 通路已被确定为多种癌症发展的关键因素。目前已知 Smoothened（Smo）抑制剂可有益地干扰 Hedgehog 通路，并正在作为许多肿瘤实体的抗癌药物进行研究。本文综述了 Smo 抑制剂在治疗晚期基底细胞癌（BCC）方面的最新临床研究进展。
在回顾过去 12 个月的文献时，令人震惊的是看到该领域的快速发展。12 个月前被认为是强有力新药候选物的化合物现在已经被淘汰，而新的化合物又出现了。确定了 13 种药物候选物的报告：一种已上市的维莫德吉（vismodegib），八种目前正在开发中（I 期-II 期），四种目前正在为 BCC 进行临床研究。
Smo 抑制剂是治疗 BCC 的一种有前途的药物类别。迄今为止，大多数候选药物都处于早期开发阶段，如果成功，预计将在大约 5-8 年内进入市场。
